Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Holding Its Breath On Exubera DTC Advertising To Focus On Education

Executive Summary

Pfizer will begin direct-to-consumer advertising for its inhaled insulin therapy Exubera approximately one year after its approval, the company said at a June 10 briefing in Washington, D.C

You may also be interested in...



Lilly Diabetes Sales Growth Slows; Newer Products Take The Lead

Despite efforts to strengthen its position in the diabetes market, revenue from Lilly's diabetes care franchise - Humulin, Humalog, Actos and Byetta - increased just 5% to $701.7 mil. in the second quarter, primarily on the strength of Byetta

Lilly Diabetes Sales Growth Slows; Newer Products Take The Lead

Despite efforts to strengthen its position in the diabetes market, revenue from Lilly's diabetes care franchise - Humulin, Humalog, Actos and Byetta - increased just 5% to $701.7 mil. in the second quarter, primarily on the strength of Byetta

Pfizer Predicts Exubera, Chantix Favorable Reimbursement Despite Delays

Pfizer's Chantix and Exubera are being favorably received by payers in early formulary discussions, Senior VP-Global Pharmaceutical Finance Peter Brandt said during the company's second quarter earnings call July 20

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS047302

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel